Arcutis Biotherapeutics, Inc. (ARQT) stock
ARQTNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 4, 2026Score 11/30403% above fair value
$27.33+0.18 (+0.66%)
Close on Nov 17, 2026Market cap $3.44BP/E 124.2Yield –
Arcutis Biotherapeutics pe ratio
The price-to-earnings ratio is the share price divided by diluted earnings per share over the trailing twelve months.
Arcutis Biotherapeutics's pe ratio was 129.0× on Nov 11, 2026.
PE Ratio at the end of each year
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| 2026 | Nov 11, 2026 | 129.0× | – |
See a number that looks wrong?